Understanding Medullary Thyroid Cancer: Diagnosis and Treatment Guide

Medullary thyroid cancer (MTC) is a rare form of malignancy that accounts for approximately 1% to 2% of all thyroid cancers in the United States. Unlike the more common papillary or follicular thyroid cancers, which arise from the cells that produce thyroid hormone, MTC originates in the parafollicular cells, also known as C cells. These specialized cells are responsible for producing calcitonin, a hormone that helps regulate calcium levels in the blood.

Because MTC arises from C cells rather than follicular cells, it behaves differently than other thyroid malignancies. Most notably, it does not absorb iodine. This means that radioactive iodine (RAI) therapy — a staple treatment for other thyroid cancers — is ineffective against MTC. This distinction makes early diagnosis and a specialized treatment plan essential for patient success.

MTC generally presents in two distinct clinical forms:

• Sporadic MTC: This accounts for roughly 75% of cases. It typically occurs in adults in their 40s or 50s and is not inherited.
• Hereditary MTC: This accounts for the remaining 25% and is caused by an inherited mutation in the RET proto-oncogene. These cases are often part of a genetic syndrome called Multiple Endocrine Neoplasia type 2 (MEN2). Because of the hereditary link, family members of affected individuals often undergo genetic screening.

Diagnosis and Clinical Staging

The journey to a diagnosis usually begins when a patient or physician feels a lump in the neck, or when a nodule is found incidentally during imaging for an unrelated issue. Because MTC can be aggressive, a thorough diagnostic workup is vital.

• Fine-Needle Aspiration (FNA): A biopsy where a thin needle removes cells from the thyroid nodule. Under a microscope, pathologists look for the distinct amyloid deposits and spindle cells characteristic of MTC.
• Serum Marker Testing: MTC is unique because it has "built-in" tumor markers. Doctors measure levels of calcitonin and carcinoembryonic antigen (CEA) in the blood. High levels can suggest the presence of MTC and help track the effectiveness of treatments later on.
• Genetic Counseling: Guidelines recommend that every patient diagnosed with MTC undergo genetic testing for the RET mutation. This determines if the patient has the hereditary form, which may necessitate screening for other tumors (like pheochromocytoma) and testing for family members.
• Imaging: Ultrasound is used to map the thyroid and nearby lymph nodes. In cases where blood markers are significantly elevated, CT scans, MRIs or PET scans may be used to check for spread to the lungs, liver, or bones.

Treatment Options

The management of MTC is primarily surgical, especially in the early stages. Because MTC is resistant to both iodine and most traditional chemotherapies, the initial operation is the best chance for a cure.

1. Surgical Intervention

The standard treatment is a total thyroidectomy. Surgeons typically also perform a central neck dissection to remove lymph nodes near the thyroid, as MTC has a high tendency to spread to the lymphatic system early in the disease process. If imaging shows spread to the sides of the neck, a lateral neck dissection may also be required.

2. Targeted Molecular Therapy

For patients whose cancer has spread to distant organs (metastatic disease) or cannot be removed surgically, "targeted therapies" have revolutionized care. These are not traditional chemotherapy; instead, they are Tyrosine Kinase Inhibitors (TKIs).

• Caprelsa (vandetanib) and Cabometyx (cabozantinib): Oral medications that block the signals that allow cancer cells to grow and form new blood vessels.
• RET Inhibitors: Newer drugs like Retevmo (selpercatinib) and Gavreto (pralsetinib) specifically target the RET mutation with high precision and fewer side effects than older TKIs.

Adverse Effects and Long-Term Management

Living with MTC requires a proactive approach to managing the side effects of treatment and surgery.

• Hormonal Replacement: Since the thyroid is removed, patients must take a daily synthetic hormone (levothyroxine) for the rest of their lives to maintain normal metabolism.
• Calcium Regulation: The parathyroid glands, which sit behind the thyroid, can be bruised or removed during surgery. This leads to hypocalcemia (low blood calcium), which may require lifelong calcium and vitamin D supplementation.
• TKI Toxicities: Targeted therapies can cause unique side effects, including high blood pressure, diarrhea, fatigue and "hand-foot syndrome" (redness or blistering on the palms and soles).
• Monitoring: Patients will have "surveillance" blood tests every few months to monitor calcitonin and CEA levels. A rising trend in these markers often signals the need for new imaging.

Conclusion

While a medullary thyroid cancer diagnosis is a significant life event, the landscape of treatment is rapidly evolving. The shift toward precision medicine and genomic testing allows for more personalized care than ever before. Educating yourself on your specific markers and genetic status is the best way to partner with your oncology team to navigate this journey.

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.